speb/financial-data huggingface dataset:
LAB cash_flow (annual, 2024-12-31) — Preferred Stock Issuance: 0.00
LAB income_statement (annual, 2024-12-31) — Pretax Income: -90397000.00
LAB cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 2070000.00
LAB balance_sheet (annual, 2024-12-31) — Properties: 0.00
LAB cash_flow (annual, 2024-12-31) — Provisionand Write Offof Assets: 2524000.00
LAB cash_flow (annual, 2024-12-31) — Purchase Of Business: -1385000.00
LAB cash_flow (annual, 2024-12-31) — Purchase Of Investment: -256119000.00
LAB cash_flow (annual, 2024-12-31) — Purchase Of PPE: -8355000.00
LAB balance_sheet (annual, 2024-12-31) — Raw Materials: 13041000.00
LAB balance_sheet (quarterly, 2024-12-31) — Raw Materials: 13041000.00
LAB balance_sheet (annual, 2024-12-31) — Receivables: 14741000.00
LAB income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 46125000.00
LAB income_statement (annual, 2024-12-31) — Reconciled Depreciation: 16861000.00
LAB cash_flow (annual, 2024-12-31) — Repayment Of Debt: -63192000.00
LAB cash_flow (quarterly, 2024-12-31) — Repayment Of Debt: -55000000.00
LAB cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -40490000.00
LAB cash_flow (quarterly, 2024-12-31) — Repurchase Of Capital Stock: 0.00
LAB income_statement (annual, 2024-12-31) — Research And Development: 28831000.00
LAB income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 15266000.00
LAB balance_sheet (annual, 2024-12-31) — Retained Earnings: -1185651000.00
LAB cash_flow (annual, 2024-12-31) — Sale Of Business: 280033000.00
LAB cash_flow (annual, 2024-12-31) — Sale Of Investment: 349000000.00
LAB income_statement (annual, 2024-12-31) — Selling General And Administration: 103058000.00
LAB balance_sheet (annual, 2024-12-31) — Share Issued: 396110000.00
LAB cash_flow (annual, 2024-12-31) — Short Term Debt Payments: -63192000.00
LAB income_statement (annual, 2024-12-31) — Special Income Charges: -15266000.00
LAB cash_flow (annual, 2024-12-31) — Stock Based Compensation: 31732000.00
LAB balance_sheet (annual, 2024-12-31) — Stockholders Equity: 471722000.00
LAB balance_sheet (annual, 2024-12-31) — Tangible Book Value: 471722000.00
LAB income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -3205860.00
LAB income_statement (annual, 2024-12-31) — Tax Provision: 542000.00
LAB income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
LAB balance_sheet (annual, 2024-12-31) — Total Assets: 612345000.00
LAB balance_sheet (annual, 2024-12-31) — Total Capitalization: 472021000.00
LAB balance_sheet (annual, 2024-12-31) — Total Debt: 30695000.00
LAB balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 471722000.00
LAB income_statement (annual, 2024-12-31) — Total Expenses: 178014000.00
LAB balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 140623000.00
LAB balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 236462000.00
LAB balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 74728000.00
LAB income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -127485000.00
LAB balance_sheet (annual, 2024-12-31) — Total Tax Payable: 1581000.00
LAB balance_sheet (quarterly, 2024-12-31) — Total Tax Payable: 1581000.00
LAB income_statement (annual, 2024-12-31) — Total Unusual Items: -15266000.00
LAB income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -15266000.00
LAB balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 18580000.00
LAB balance_sheet (annual, 2024-12-31) — Treasury Stock: 46467000.00
LAB cash_flow (annual, 2024-12-31) — Unrealized Gain Loss On Investment Securities: 0.00
LAB balance_sheet (annual, 2024-12-31) — Work In Process: 443000.00
LAB balance_sheet (quarterly, 2024-12-31) — Work In Process: 443000.00
LAB balance_sheet (annual, 2024-12-31) — Working Capital: 309988000.00
LAB income_statement (quarterly, 2025-03-31) — +Operating Expense: 35264000.00
LAB income_statement (quarterly, 2025-03-31) — +Total Revenue: 20222000.00
LAB balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 11778000.00
LAB balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 30611000.00
LAB balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -77063000.00
LAB balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1711180000.00
LAB cash_flow (quarterly, 2025-03-31) — Amortization Cash Flow: 898000.00
LAB cash_flow (quarterly, 2025-03-31) — Amortization Of Intangibles: 898000.00
LAB cash_flow (quarterly, 2025-03-31) — Amortization Of Securities: -841000.00
LAB income_statement (quarterly, 2025-03-31) — Basic Average Shares: 378228000.00
LAB income_statement (quarterly, 2025-03-31) — Basic EPS: -0.07
LAB cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 168818000.00
LAB cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -5054000.00
LAB balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 31231000.00
LAB balance_sheet (quarterly, 2025-03-31) — Capital Stock: 397000.00
LAB balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 150880000.00
LAB balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 258062000.00
LAB cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -46000.00
LAB cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 14625000.00
LAB cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -30283000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -578000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -7753000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Inventory: -3817000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -1401000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -527000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Payable: -578000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -8331000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 112000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Receivables: -1631000.00
LAB cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -15595000.00
LAB cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: -2021000.00
LAB cash_flow (quarterly, 2025-03-31) — Changes In Cash: -15704000.00
LAB balance_sheet (quarterly, 2025-03-31) — Common Stock: 397000.00
LAB balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 454595000.00
LAB cash_flow (quarterly, 2025-03-31) — Common Stock Payments: 0.00
LAB balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 6992000.00
LAB income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 9173000.00
LAB balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 11460000.00
LAB balance_sheet (quarterly, 2025-03-31) — Current Assets: 344019000.00
LAB balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 6334000.00
LAB balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 6334000.00
LAB balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 17326000.00
LAB balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 17326000.00
LAB balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 56236000.00
LAB cash_flow (quarterly, 2025-03-31) — Depreciation: 3273000.00
LAB cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 4171000.00
LAB cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 4171000.00
LAB income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 378228000.00
LAB income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.07
LAB income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -26033000.00
LAB income_statement (quarterly, 2025-03-31) — EBIT: -24215000.00
LAB income_statement (quarterly, 2025-03-31) — EBITDA: -20044000.00
LAB cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 357000.00
LAB cash_flow (quarterly, 2025-03-31) — End Cash Position: 153471000.00
LAB cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -46000.00
LAB cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -35337000.00
LAB cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: -232000.00
LAB cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of Business: 0.00
LAB balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 1169000.00
LAB balance_sheet (quarterly, 2025-03-31) — Goodwill: 111719000.00
LAB balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 139776000.00
LAB balance_sheet (quarterly, 2025-03-31) — Gross PPE: 148078000.00
LAB income_statement (quarterly, 2025-03-31) — Gross Profit: 11049000.00
LAB cash_flow (quarterly, 2025-03-31) — Income Tax Paid Supplemental Data: 201000.00
LAB income_statement (quarterly, 2025-03-31) — Interest Expense: 2000.00
LAB income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 2000.00
LAB income_statement (quarterly, 2025-03-31) — Interest Income: 2914000.00
LAB income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 2914000.00
LAB cash_flow (quarterly, 2025-03-31) — Interest Paid Supplemental Data: 4000.00
LAB balance_sheet (quarterly, 2025-03-31) — Inventory: 42125000.00
LAB balance_sheet (quarterly, 2025-03-31) — Invested Capital: 454894000.00
LAB cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 14625000.00
LAB balance_sheet (quarterly, 2025-03-31) — Leases: 17472000.00
LAB balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 24897000.00
LAB balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 299000.00
LAB balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 25196000.00
LAB cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: 0.00
LAB balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 35547000.00
LAB cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: 0.00
LAB cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 0.00
LAB income_statement (quarterly, 2025-03-31) — Net Income: -26033000.00
LAB income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -26033000.00
LAB income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -23370000.00
LAB income_statement (quarterly, 2025-03-31) — Net Income Discontinuous Operations: -2663000.00
LAB income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -26033000.00
LAB income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -23370000.00
LAB cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -26033000.00
LAB income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -26033000.00
LAB income_statement (quarterly, 2025-03-31) — Net Interest Income: 2914000.00
LAB cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 19679000.00
LAB cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: 0.00
LAB cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: 0.00
LAB income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 2914000.00
LAB cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -46000.00
LAB balance_sheet (quarterly, 2025-03-31) — Net PPE: 71015000.00
LAB cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -5054000.00
LAB balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 314819000.00
LAB balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 40080000.00
LAB balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 39049000.00
LAB balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1031000.00
LAB income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -17289000.00
LAB income_statement (quarterly, 2025-03-31) — Normalized Income: -20628957.38
LAB cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -30283000.00
LAB cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -232000.00
LAB income_statement (quarterly, 2025-03-31) — Operating Income: -24215000.00
LAB income_statement (quarterly, 2025-03-31) — Operating Revenue: 20222000.00
LAB balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 379087000.00
LAB balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 8352000.00
LAB balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 1169000.00
LAB income_statement (quarterly, 2025-03-31) — Other Income Expense: -2188000.00
LAB balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 28057000.00
LAB cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: -1577000.00
LAB balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 24787000.00
LAB balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 3490000.00
LAB income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 567000.00
LAB balance_sheet (quarterly, 2025-03-31) — Other Properties: 88067000.00
LAB balance_sheet (quarterly, 2025-03-31) — Other Receivables: 6099000.00
LAB balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 107182000.00
LAB balance_sheet (quarterly, 2025-03-31) — Payables: 11778000.00
LAB balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 23238000.00
LAB balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 9338000.00
LAB balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
LAB income_statement (quarterly, 2025-03-31) — Pretax Income: -23489000.00
LAB cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 0.00
LAB balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
LAB cash_flow (quarterly, 2025-03-31) — Provisionand Write Offof Assets: 815000.00
LAB cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -32321000.00
LAB cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -5054000.00
LAB balance_sheet (quarterly, 2025-03-31) — Receivables: 35480000.00
LAB balance_sheet (quarterly, 2025-03-31) — Receivables Adjustments Allowances: -1230000.00
LAB income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 9173000.00
LAB income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 4171000.00
LAB cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: 0.00
LAB cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: 0.00
LAB income_statement (quarterly, 2025-03-31) — Research And Development: 5440000.00
LAB income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 2755000.00
LAB balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -1211684000.00
LAB cash_flow (quarterly, 2025-03-31) — Sale Of Business: 0.00
LAB cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 52000000.00
LAB income_statement (quarterly, 2025-03-31) — Selling General And Administration: 29824000.00
LAB balance_sheet (quarterly, 2025-03-31) — Share Issued: 397667000.00
LAB income_statement (quarterly, 2025-03-31) — Special Income Charges: -2755000.00
LAB cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 9009000.00
LAB balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 454595000.00
LAB balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 314819000.00
LAB income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -13957.38
LAB income_statement (quarterly, 2025-03-31) — Tax Provision: -119000.00
LAB income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.01
LAB balance_sheet (quarterly, 2025-03-31) — Total Assets: 579597000.00
LAB balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 454894000.00
LAB balance_sheet (quarterly, 2025-03-31) — Total Debt: 31530000.00
LAB balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 454595000.00
LAB income_statement (quarterly, 2025-03-31) — Total Expenses: 44437000.00
LAB balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 125002000.00
LAB balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 235578000.00
LAB balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 68766000.00
LAB income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -26970000.00
LAB income_statement (quarterly, 2025-03-31) — Total Unusual Items: -2755000.00
LAB income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -2755000.00
LAB balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 18580000.00
LAB balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 46467000.00
LAB cash_flow (quarterly, 2025-03-31) — Unrealized Gain Loss On Investment Securities: 0.00
LAB balance_sheet (quarterly, 2025-03-31) — Working Capital: 287783000.00
LAB income_statement (quarterly, 2025-06-30) — +Operating Expense: 34327000.00
LAB income_statement (quarterly, 2025-06-30) — +Total Revenue: 21762000.00
LAB balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 7329000.00
LAB balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 14612000.00
LAB balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -44982000.00
LAB balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1717673000.00
LAB balance_sheet (quarterly, 2025-06-30) — Allowance For Doubtful Accounts Receivable: -352000.00
LAB cash_flow (quarterly, 2025-06-30) — Amortization Cash Flow: 817000.00
LAB cash_flow (quarterly, 2025-06-30) — Amortization Of Intangibles: 817000.00
LAB balance_sheet (quarterly, 2025-06-30) — Assets Held For Sale Current: 223089000.00
LAB income_statement (quarterly, 2025-06-30) — Basic Average Shares: 380498000.00
LAB income_statement (quarterly, 2025-06-30) — Basic EPS: -0.09
LAB cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 153471000.00
LAB cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -1887000.00
LAB balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 28317000.00
LAB balance_sheet (quarterly, 2025-06-30) — Capital Stock: 400000.00
LAB balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 158617000.00
LAB balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 237085000.00
LAB cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 108000.00
LAB cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 27505000.00
LAB cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -20668000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 1416000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: 9238000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Inventory: -4731000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -1521000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: -1373000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Payable: 1416000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 10654000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -1287000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Receivables: -666000.00
LAB cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 1076000.00
LAB cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -276000.00
LAB cash_flow (quarterly, 2025-06-30) — Changes In Cash: 6945000.00
LAB balance_sheet (quarterly, 2025-06-30) — Common Stock: 400000.00
LAB balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 424535000.00
LAB cash_flow (quarterly, 2025-06-30) — Common Stock Payments: 0.00
LAB balance_sheet (quarterly, 2025-06-30) — Construction In Progress: 473000.00
LAB income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 11134000.00
LAB balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 13259000.00
LAB balance_sheet (quarterly, 2025-06-30) — Current Assets: 506037000.00
LAB balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 5094000.00
LAB balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 5094000.00
LAB balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 44299000.00
LAB balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 44299000.00
LAB balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 98024000.00
LAB cash_flow (quarterly, 2025-06-30) — Depreciation: 3177000.00
LAB cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 3994000.00
LAB cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 3994000.00
LAB income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 380498000.00
LAB income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.09
LAB income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -33459000.00
LAB income_statement (quarterly, 2025-06-30) — EBIT: -18273000.00
LAB income_statement (quarterly, 2025-06-30) — EBITDA: -14279000.00
LAB cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 788000.00
LAB cash_flow (quarterly, 2025-06-30) — End Cash Position: 161204000.00
LAB cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 108000.00
LAB balance_sheet (quarterly, 2025-06-30) — Finished Goods: 13948000.00
LAB cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -22555000.00
LAB cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: 0.00
LAB balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -1928000.00
LAB balance_sheet (quarterly, 2025-06-30) — Gross Accounts Receivable: 14964000.00
LAB balance_sheet (quarterly, 2025-06-30) — Gross PPE: 92228000.00
LAB income_statement (quarterly, 2025-06-30) — Gross Profit: 10628000.00
LAB cash_flow (quarterly, 2025-06-30) — Income Tax Paid Supplemental Data: -181000.00
LAB income_statement (quarterly, 2025-06-30) — Interest Expense: 9000.00
LAB income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 9000.00
LAB income_statement (quarterly, 2025-06-30) — Interest Income: 2461000.00
LAB income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 2461000.00
LAB cash_flow (quarterly, 2025-06-30) — Interest Paid Supplemental Data: 6000.00
LAB balance_sheet (quarterly, 2025-06-30) — Inventory: 24170000.00
LAB balance_sheet (quarterly, 2025-06-30) — Invested Capital: 424834000.00
LAB cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 27505000.00
LAB balance_sheet (quarterly, 2025-06-30) — Leases: 14070000.00
LAB balance_sheet (quarterly, 2025-06-30) — Liabilities Heldfor Sale Non Current: 0.00
LAB balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 23223000.00
LAB balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 299000.00
LAB balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 23522000.00
LAB cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: 0.00
LAB balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 17185000.00
LAB cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 0.00
LAB income_statement (quarterly, 2025-06-30) — Net Income: -33459000.00
LAB income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -33459000.00
LAB income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -17673000.00
LAB income_statement (quarterly, 2025-06-30) — Net Income Discontinuous Operations: -15786000.00
LAB income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -33459000.00
LAB income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -17673000.00
LAB cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -33459000.00
LAB income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -33459000.00
LAB income_statement (quarterly, 2025-06-30) — Net Interest Income: 2452000.00
LAB cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 29392000.00
LAB cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: 0.00
LAB cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: 0.00
LAB income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 2452000.00
LAB cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -200000.00
LAB balance_sheet (quarterly, 2025-06-30) — Net PPE: 47246000.00
LAB cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -1887000.00
LAB balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 424535000.00
LAB balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 9634000.00
LAB balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Revenue: 8553000.00
LAB balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 1081000.00
LAB income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -12281000.00
LAB income_statement (quarterly, 2025-06-30) — Normalized Income: -15741556.28
LAB cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -20668000.00
LAB cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 0.00
LAB income_statement (quarterly, 2025-06-30) — Operating Income: -23699000.00
LAB income_statement (quarterly, 2025-06-30) — Operating Revenue: 21762000.00
LAB balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 381691000.00
LAB balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 7081000.00
LAB balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 17984000.00
LAB balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -1928000.00
LAB income_statement (quarterly, 2025-06-30) — Other Income Expense: 2965000.00
LAB cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: -52000.00
LAB balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 3682000.00
LAB balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 1250000.00
LAB income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 4963000.00
LAB balance_sheet (quarterly, 2025-06-30) — Other Properties: 60500000.00
LAB balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 78468000.00
LAB balance_sheet (quarterly, 2025-06-30) — Payables: 7329000.00
LAB balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 20588000.00
LAB balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 10059000.00
LAB balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
LAB income_statement (quarterly, 2025-06-30) — Pretax Income: -18282000.00
LAB cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 308000.00
LAB balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
LAB cash_flow (quarterly, 2025-06-30) — Provisionand Write Offof Assets: 545000.00
LAB cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -18608000.00
LAB cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -1887000.00
LAB balance_sheet (quarterly, 2025-06-30) — Raw Materials: 9808000.00
LAB balance_sheet (quarterly, 2025-06-30) — Receivables: 14612000.00
LAB income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 11134000.00
LAB income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 3994000.00
LAB cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: 0.00
LAB cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: 0.00
LAB income_statement (quarterly, 2025-06-30) — Research And Development: 6222000.00
LAB income_statement (quarterly, 2025-06-30) — Restructuring And Mergern Acquisition: 1998000.00
LAB balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -1245143000.00
LAB cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 48000000.00
LAB income_statement (quarterly, 2025-06-30) — Selling General And Administration: 28105000.00
LAB balance_sheet (quarterly, 2025-06-30) — Share Issued: 400271000.00
LAB income_statement (quarterly, 2025-06-30) — Special Income Charges: -1998000.00
LAB cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 6387000.00
LAB balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 424535000.00
LAB balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 424535000.00
LAB income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -66556.28
LAB income_statement (quarterly, 2025-06-30) — Tax Provision: -609000.00
LAB income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.03
LAB balance_sheet (quarterly, 2025-06-30) — Total Assets: 556965000.00
LAB balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 424834000.00
LAB balance_sheet (quarterly, 2025-06-30) — Total Debt: 28616000.00
LAB balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 424535000.00
LAB income_statement (quarterly, 2025-06-30) — Total Expenses: 45461000.00
LAB balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 132430000.00
LAB balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 50928000.00
LAB balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 34406000.00
LAB income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -25697000.00
LAB income_statement (quarterly, 2025-06-30) — Total Unusual Items: -1998000.00
LAB income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -1998000.00
LAB balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 18580000.00
LAB balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 46467000.00
LAB balance_sheet (quarterly, 2025-06-30) — Work In Process: 414000.00
LAB balance_sheet (quarterly, 2025-06-30) — Working Capital: 408013000.00
LAB income_statement (quarterly, 2025-09-30) — +Operating Expense: 32951000.00
LAB income_statement (quarterly, 2025-09-30) — +Total Revenue: 19552000.00
LAB balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 6619000.00
LAB balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 13536000.00
LAB balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -47075000.00
LAB balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 1726032000.00
LAB balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -397000.00
LAB cash_flow (quarterly, 2025-09-30) — Amortization Cash Flow: 0.00
LAB cash_flow (quarterly, 2025-09-30) — Amortization Of Intangibles: 0.00
LAB balance_sheet (quarterly, 2025-09-30) — Assets Held For Sale Current: 230676000.00
LAB income_statement (quarterly, 2025-09-30) — Basic Average Shares: 382630000.00
LAB income_statement (quarterly, 2025-09-30) — Basic EPS: -0.09
LAB cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 161204000.00
LAB cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -886000.00
LAB balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 27090000.00
LAB balance_sheet (quarterly, 2025-09-30) — Capital Stock: 401000.00
LAB balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 129418000.00
LAB balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 194903000.00
LAB cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -112000.00
LAB cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -6681000.00
LAB cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -22202000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 946000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 8774000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Inventory: -1804000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -1646000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: 700000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Payable: 946000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 9720000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -705000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Receivables: -5794000.00
LAB cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 471000.00
LAB cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -5794000.00
LAB cash_flow (quarterly, 2025-09-30) — Changes In Cash: -28995000.00
LAB balance_sheet (quarterly, 2025-09-30) — Common Stock: 401000.00
LAB balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 399659000.00
LAB cash_flow (quarterly, 2025-09-30) — Common Stock Payments: 0.00
LAB balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 375000.00
LAB income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 10068000.00
LAB balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 16351000.00
LAB balance_sheet (quarterly, 2025-09-30) — Current Assets: 472439000.00
LAB balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 5113000.00
LAB balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 5113000.00
LAB balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 44108000.00
LAB balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 44108000.00
LAB balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 107965000.00
LAB cash_flow (quarterly, 2025-09-30) — Depreciation: 1521000.00
LAB cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 1521000.00
LAB cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 1521000.00
LAB income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 382630000.00
LAB income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.09
LAB income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -34687000.00
LAB income_statement (quarterly, 2025-09-30) — EBIT: -32890000.00
LAB income_statement (quarterly, 2025-09-30) — EBITDA: -31369000.00
LAB cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -203000.00
LAB cash_flow (quarterly, 2025-09-30) — End Cash Position: 132006000.00
LAB cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -112000.00
LAB balance_sheet (quarterly, 2025-09-30) — Finished Goods: 12680000.00
LAB cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -23088000.00
LAB cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: 0.00
LAB balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -477000.00
LAB balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 13933000.00
LAB balance_sheet (quarterly, 2025-09-30) — Gross PPE: 91266000.00
LAB income_statement (quarterly, 2025-09-30) — Gross Profit: 9484000.00
LAB income_statement (quarterly, 2025-09-30) — Interest Expense: 10000.00
LAB income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 10000.00
LAB income_statement (quarterly, 2025-09-30) — Interest Income: 2140000.00
LAB income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 2140000.00
LAB cash_flow (quarterly, 2025-09-30) — Interest Paid Supplemental Data: 5000.00
LAB balance_sheet (quarterly, 2025-09-30) — Inventory: 25418000.00
LAB balance_sheet (quarterly, 2025-09-30) — Invested Capital: 399958000.00
LAB cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -6681000.00
LAB balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 19485000.00
LAB balance_sheet (quarterly, 2025-09-30) — Leases: 13974000.00
LAB balance_sheet (quarterly, 2025-09-30) — Liabilities Heldfor Sale Non Current: 0.00
LAB balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 21977000.00
LAB balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 299000.00
LAB balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 22276000.00
LAB cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: 0.00
LAB balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 17177000.00
LAB cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 0.00
LAB income_statement (quarterly, 2025-09-30) — Net Income: -34687000.00
LAB income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -34687000.00
LAB income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -31684000.00
LAB income_statement (quarterly, 2025-09-30) — Net Income Discontinuous Operations: -3003000.00
LAB income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -34687000.00
LAB income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -31684000.00
LAB cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -34687000.00
LAB income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -34687000.00
LAB income_statement (quarterly, 2025-09-30) — Net Interest Income: 2130000.00
LAB cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: -5795000.00
LAB cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: 0.00
LAB cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: 0.00
LAB income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 2130000.00
LAB cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -112000.00
LAB balance_sheet (quarterly, 2025-09-30) — Net PPE: 44191000.00
LAB cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -886000.00
LAB balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 399659000.00
LAB balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 8536000.00
LAB balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 7397000.00
LAB balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 1139000.00
LAB income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -21898000.00
LAB income_statement (quarterly, 2025-09-30) — Normalized Income: -22563052.77
LAB cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -22202000.00
LAB cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 0.00
LAB income_statement (quarterly, 2025-09-30) — Operating Income: -23467000.00
LAB income_statement (quarterly, 2025-09-30) — Operating Revenue: 19552000.00
LAB balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 383614000.00
LAB balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 7906000.00
LAB balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 22214000.00
LAB balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -477000.00
LAB income_statement (quarterly, 2025-09-30) — Other Income Expense: -11563000.00
LAB cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 1404000.00
LAB balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 3521000.00
LAB balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 1200000.00
LAB income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -2092000.00
LAB balance_sheet (quarterly, 2025-09-30) — Other Properties: 59740000.00
LAB balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 65485000.00
LAB balance_sheet (quarterly, 2025-09-30) — Payables: 6619000.00
LAB balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 22970000.00
LAB balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 13560000.00
LAB balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
LAB income_statement (quarterly, 2025-09-30) — Pretax Income: -32900000.00
LAB cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 0.00
LAB balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
LAB cash_flow (quarterly, 2025-09-30) — Provisionand Write Offof Assets: 615000.00
LAB cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -59795000.00
LAB cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -886000.00
LAB balance_sheet (quarterly, 2025-09-30) — Raw Materials: 12468000.00
LAB balance_sheet (quarterly, 2025-09-30) — Receivables: 13536000.00
LAB income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 10068000.00
LAB income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 1521000.00
LAB cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: 0.00
LAB cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: 0.00
LAB income_statement (quarterly, 2025-09-30) — Research And Development: 6356000.00
LAB income_statement (quarterly, 2025-09-30) — Restructuring And Mergern Acquisition: 9471000.00
LAB balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -1279830000.00
LAB cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 54000000.00
LAB income_statement (quarterly, 2025-09-30) — Selling General And Administration: 26595000.00
LAB balance_sheet (quarterly, 2025-09-30) — Share Issued: 402194000.00
LAB income_statement (quarterly, 2025-09-30) — Special Income Charges: -9471000.00
LAB cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 8474000.00
LAB balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 399659000.00
LAB balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 399659000.00
LAB income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -350052.77
LAB income_statement (quarterly, 2025-09-30) — Tax Provision: -1216000.00
LAB income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.04
LAB balance_sheet (quarterly, 2025-09-30) — Total Assets: 539636000.00
LAB balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 399958000.00
LAB balance_sheet (quarterly, 2025-09-30) — Total Debt: 27389000.00
LAB balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 399659000.00
LAB income_statement (quarterly, 2025-09-30) — Total Expenses: 43019000.00
LAB balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 139977000.00
LAB balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 67197000.00
LAB balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 32012000.00
LAB income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -32938000.00
LAB income_statement (quarterly, 2025-09-30) — Total Unusual Items: -9471000.00
LAB income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -9471000.00
LAB balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 18580000.00
LAB balance_sheet (quarterly, 2025-09-30) — Treasury Stock: 46467000.00
LAB balance_sheet (quarterly, 2025-09-30) — Work In Process: 270000.00
LAB balance_sheet (quarterly, 2025-09-30) — Working Capital: 364474000.00
LAB income_statement (annual, 2025-12-31) — +Operating Expense: 135848000.00
LAB income_statement (quarterly, 2025-12-31) — +Operating Expense: 33306000.00
LAB income_statement (annual, 2025-12-31) — +Total Revenue: 85331000.00
LAB income_statement (quarterly, 2025-12-31) — +Total Revenue: 23795000.00
LAB balance_sheet (annual, 2025-12-31) — Accounts Payable: 5407000.00
LAB balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 5407000.00
LAB balance_sheet (annual, 2025-12-31) — Accounts Receivable: 13431000.00
LAB balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 13431000.00
LAB balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -48162000.00
LAB balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -48162000.00
LAB balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 1732393000.00
LAB balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 1732393000.00
LAB balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -284000.00
LAB balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -284000.00
LAB cash_flow (annual, 2025-12-31) — Amortization Cash Flow: 1715000.00
LAB cash_flow (quarterly, 2025-12-31) — Amortization Cash Flow: 0.00
LAB cash_flow (annual, 2025-12-31) — Amortization Of Intangibles: 1715000.00
LAB cash_flow (quarterly, 2025-12-31) — Amortization Of Intangibles: 0.00
LAB cash_flow (annual, 2025-12-31) — Amortization Of Securities: -2644000.00
LAB balance_sheet (annual, 2025-12-31) — Assets Held For Sale Current: 228406000.00
LAB balance_sheet (quarterly, 2025-12-31) — Assets Held For Sale Current: 228406000.00
LAB income_statement (annual, 2025-12-31) — Basic Average Shares: 381623000.00
LAB income_statement (quarterly, 2025-12-31) — Basic Average Shares: 385048000.00
LAB income_statement (annual, 2025-12-31) — Basic EPS: -0.20
LAB income_statement (quarterly, 2025-12-31) — Basic EPS: 0.05
LAB cash_flow (annual, 2025-12-31) — Beginning Cash Position: 168818000.00
LAB cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 132006000.00
LAB cash_flow (annual, 2025-12-31) — Capital Expenditure: -8303000.00
LAB cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -476000.00
LAB balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 30528000.00
LAB balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 30528000.00
LAB balance_sheet (annual, 2025-12-31) — Capital Stock: 404000.00
LAB balance_sheet (quarterly, 2025-12-31) — Capital Stock: 404000.00
LAB balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 120863000.00
LAB balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 120863000.00
LAB balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 187575000.00
LAB balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 187575000.00
LAB cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 570000.00
LAB cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 620000.00
LAB cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: 27409000.00
LAB cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -8040000.00
LAB cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -74343000.00
LAB cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -1190000.00
LAB cash_flow (annual, 2025-12-31) — Change In Account Payable: 2437000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 653000.00
LAB cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 10357000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 98000.00
LAB cash_flow (annual, 2025-12-31) — Change In Inventory: -11524000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Inventory: -1172000.00
LAB cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -6623000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -2055000.00
LAB cash_flow (annual, 2025-12-31) — Change In Other Working Capital: -1314000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: -114000.00
LAB cash_flow (annual, 2025-12-31) — Change In Payable: 2437000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Payable: 653000.00
LAB cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 12794000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 751000.00
LAB cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 1143000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 3023000.00
LAB cash_flow (annual, 2025-12-31) — Change In Receivables: -39454000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Receivables: -31363000.00
LAB cash_flow (annual, 2025-12-31) — Change In Working Capital: -44978000.00
LAB cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -30930000.00
LAB cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -1361000.00
LAB cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: 6730000.00
LAB cash_flow (annual, 2025-12-31) — Changes In Cash: -46364000.00
LAB cash_flow (quarterly, 2025-12-31) — Changes In Cash: -8610000.00
LAB balance_sheet (annual, 2025-12-31) — Common Stock: 404000.00
LAB balance_sheet (quarterly, 2025-12-31) — Common Stock: 404000.00
LAB balance_sheet (annual, 2025-12-31) — Common Stock Equity: 424291000.00
LAB balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 424291000.00
LAB cash_flow (annual, 2025-12-31) — Common Stock Payments: 0.00
LAB cash_flow (quarterly, 2025-12-31) — Common Stock Payments: 0.00
LAB balance_sheet (annual, 2025-12-31) — Construction In Progress: 900000.00